Shiny, new and expensive: ESMO studies find new cancer drugs carry higher prices, add little benefit

Here's a finding to add to the drug pricing debate: New cancer meds often add little benefit for patients, but carry higher prices than existing drugs. Researchers unveiled the study results as ESMO Congress 2019 gets underway in Barcelona.